Nasdaq

Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data on the development of ARO-DUX4, the company’s investigational RNA interference (RNAi ...
Nasdaq

Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced ARO-DUX4 as Arrowhead’s first muscle targeted investigational RNAi therapeutic candidate to utilize ...
BioWorld

Arrowhead seeks clearance to begin clinical study of ARO-DUX4 for facioscapulohumeral muscular dystrophy

Arrowhead Pharmaceuticals Inc. has filed an application in New Zealand for clearance to initiate a phase I/II trial of ARO-DUX4, the company’s investigational RNA interference (RNAi) therapeutic being ...
Mena FN

Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Gains Momentum: 10+ Companies Lead The Charge In Pioneering New Treatments Delveinsight

DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...
Mena FN

Facioscapulohumeral Muscular Dystrophy Clinical Trial Pipeline Shows Potential With Active Contributions From 10+ Key Companies Delveinsight

DelveInsight's“ Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in the Facioscapulohumeral Muscular ...